Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth.
about
Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant womenIs protease inhibitors based antiretroviral therapy during pregnancy associated with an increased risk of preterm birth? Systematic review and a meta-analysisAntiretroviral Therapy and Pregnancy Outcomes in Developing Countries: A Systematic ReviewAssociation between in utero zidovudine exposure and nondefect adverse birth outcomes: analysis of prospectively collected data from the Antiretroviral Pregnancy Registry.Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trialPregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conceptionMaternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI perinatal study.Predictors of adverse pregnancy outcomes in women infected with HIV in Latin America and the Caribbean: a cohort study.Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy.Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana.Antenatal atazanavir: a retrospective analysis of pregnancies exposed to atazanavir.Antiretroviral regimens in pregnancy and breast-feeding in Botswana.Incidence of and socio-biologic risk factors for spontaneous preterm birth in HIV positive Nigerian women.Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in BotswanaIncreased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancyRisk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy.Mother-to-child transmission of human immunodeficiency virus in aten years periodEvidence of Subclinical mtDNA Alterations in HIV-Infected Pregnant Women Receiving Combination Antiretroviral Therapy Compared to HIV-Negative Pregnant Women.Trends in birth weight and gestational age for infants born to HIV-infected, antiretroviral treatment-naive women in MalawiSmall-for-gestational-age births in pregnant women with HIV, due to severity of HIV disease, not antiretroviral therapy.The NICHD International Site Development Initiative perinatal cohorts (2002-09)Option B+ for prevention of vertical HIV transmission has no influence on adverse birth outcomes in a cross-sectional cohort in Western Uganda.In Utero Exposure to Antiretroviral Drugs: Effect on Birth Weight and Growth Among HIV-exposed Uninfected Children in BrazilDuration of cART Before Delivery and Low Infant Birthweight Among HIV-Infected Women in Lusaka, Zambia.Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant womenLaboratory Abnormalities Among HIV-Exposed, Uninfected Infants: IMPAACT Protocol P1025Association of Body Mass Index of HIV-1-Infected Pregnant Women and Infant Weight, Body Mass Index, Length, and Head Circumference: The NISDI Perinatal Study.Disclosing in utero HIV/ARV exposure to the HIV-exposed uninfected adolescent: is it necessary?Responding to her question: a review of the influence of pregnancy on HIV disease progression in the context of expanded access to HAART in sub-Saharan Africa.Progesterone supplementation for HIV-positive pregnant women on protease inhibitor-based antiretroviral regimens (the ProSPAR study): a study protocol for a pilot randomized controlled trialMitochondrial toxicity and caspase activation in HIV pregnant women.Severe Vitamin D Deficiency in Human Immunodeficiency Virus-Infected Pregnant Women is Associated with Preterm Birth.Antiretroviral use during pregnancy for treatment or prophylaxis.HIV protease inhibitors in pregnancy : pharmacology and clinical use.Antiretroviral therapy and preterm birth in HIV-infected women.Adverse drug reactions associated with antiretroviral therapy during pregnancy.Perinatal Antiretroviral Exposure and Prevented Mother-to-child HIV Infections in the Era of Antiretroviral Prophylaxis in the United States, 1994-2010.Determinants and trends in perinatal human immunodeficiency virus type 1 (HIV-1) transmission in the metropolitan area of Belo Horizonte, Brazil: 1998 - 2005.Antiretroviral Therapy in Relation to Birth Outcomes among HIV-infected Women: A Cohort Study.
P2860
Q24236763-26976394-1129-4303-AAB5-97165A2B0482Q28066290-88876995-9C21-4299-B4F0-65F35312BFEAQ28080543-AE2BD77B-C27B-4122-BF71-BC14007BF5CDQ30987069-798A1668-3EEB-480E-93C0-F6B3E1CC7A8AQ33294899-9F352CF1-BE27-488C-A590-BE2A146DC061Q33811136-C4D60A2E-93EE-4299-A9C7-65B75AA67064Q33830084-6C9165D9-CF49-4ECA-B9D7-F4DFDC1A8312Q33984272-56BEF90A-AE35-479A-8CBF-1CA804C4A17EQ34146634-0E668820-FBC6-4E20-BDAE-A610F2A46D95Q34158407-9A1E8790-F04F-4555-A13B-03EE4CC2C8AEQ34306176-8E024FB5-611A-4ECF-85CC-538D5FCF5467Q34310482-7836E796-E2F4-46F3-9348-F17840723FDEQ34395082-D48989F8-BB52-4CE9-BD53-F51A3913101CQ34408889-5DB396A1-4480-4707-933C-52D367C44F7AQ34500824-DB79126E-2783-435C-8661-485D8A59EC2CQ35129403-0B3A7D43-BF67-43D7-8555-5929E6F7BFE5Q35551457-E67338F6-8316-4FAB-8321-64FF95D0063FQ35639429-490FCD29-6641-4DDE-AD3A-ECF20B3496ACQ35738557-DE5A56B9-7E0D-477A-AC0B-DD1F3C6B408BQ35897529-3B611751-3886-4BC8-BA86-3D53280ADADCQ36072127-B6D0309A-A4FA-4EBE-AB6B-E28AE27361ECQ36093757-684391B5-B02A-4B24-9B2F-AF58904E01CCQ36300046-EA08D5E2-A934-41F3-B025-3B66D090BA94Q36443769-4D5B1B0C-396B-48C7-96EA-4A4180F7E6D9Q36678190-8822640A-4667-4BC9-BD16-61CB458DA267Q36803454-8EC7CEA8-5AC4-46FE-B367-DCDC63C15EDFQ36851168-D99DC8E6-A46C-4133-825F-A27EDF676E44Q37005549-9626AE4C-5A68-428B-B584-908BFA5A9AD7Q37342120-7D97EF54-5621-4935-89B3-7F82EAC05D79Q37419150-6E24C45F-BDBA-4B26-A6BF-78CA088C805CQ37498149-9503D417-C2D8-43FF-90A3-0D92282B8E3AQ37539856-228F018B-A2E3-4FBF-8180-3429C34AB726Q37723148-BD4B7919-7C1B-4192-9042-0C32E3CD22CDQ37870932-25AA9D66-59F0-4C8D-B854-E8141D7CDA8DQ38081072-790031FB-EE01-4F7B-B83A-EC666983EA2EQ38185748-D9AD79C3-2CE6-4193-8885-18D63EDA81AAQ38267557-89F4A86A-2A4F-4FD6-9419-1B286DC0DC2CQ39281855-7FE2D342-3357-4343-890B-AAE919FC6411Q39854999-42DE06AD-17C1-4C56-A782-4213E65FA1A8Q41057198-31D1C026-892C-4CC7-A1E1-4E4E244C75D8
P2860
Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Maternal antiretroviral drugs ...... irth weight and preterm birth.
@en
Maternal antiretroviral drugs ...... irth weight and preterm birth.
@nl
type
label
Maternal antiretroviral drugs ...... irth weight and preterm birth.
@en
Maternal antiretroviral drugs ...... irth weight and preterm birth.
@nl
prefLabel
Maternal antiretroviral drugs ...... irth weight and preterm birth.
@en
Maternal antiretroviral drugs ...... irth weight and preterm birth.
@nl
P2093
P1433
P1476
Maternal antiretroviral drugs ...... irth weight and preterm birth.
@en
P2093
Edgardo G Szyld
Eduardo M Warley
Geraldo Duarte
Jennifer S Read
Laura Freimanis
NISDI Perinatal Study Group
Pedro E Cahn
René Gonin
Victor H Melo
P304
P356
10.1097/01.AIDS.0000253362.01696.9D
P407
P577
2006-11-01T00:00:00Z